Drug Patent Expirations in March 2012

*Drugs may be covered by multiple patents

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
GEODON	Pfizer	ziprasidone mesylate	4,831,031	Mar 2, 2012
GEODON	Pfizer Inc	ziprasidone hydrochloride	4,831,031	Mar 2, 2012
GEODON	Pfizer	ziprasidone hydrochloride	4,831,031	Mar 2, 2012
ZOFRAN	Glaxosmithkline	ondansetron hydrochloride	5,344,658*PED	Mar 6, 2012
GENESA	Gensia Automedics	arbutamine hydrochloride	5,395,970	Mar 7, 2012
NUTROPIN DEPOT	Genentech	somatropin recombinant	5,912,015	Mar 12, 2012
LEXAPRO	Forest Labs	escitalopram oxalate	RE34712*PED	Mar 14, 2012
AVANDIA	Sb Pharmco	rosiglitazone maleate	5,002,953*PED	Mar 17, 2012
AVANDAMET	Sb Pharmco	metformin hydrochloride; rosiglitazone maleate	5,002,953*PED	Mar 17, 2012
AVANDARYL	Sb Pharmco	glimepiride; rosiglitazone maleate	5,002,953*PED	Mar 17, 2012
BONIVA	Roche	ibandronate sodium	4,927,814	Mar 17, 2012
ERAXIS	Vicuron	anidulafungin	6,384,013	Mar 19, 2012
ERAXIS	Vicuron	anidulafungin	6,743,777	Mar 19, 2012
VALTURNA	Novartis	aliskiren hemifumarate; valsartan	5,399,578	Mar 21, 2012
GABITRIL	Cephalon	tiagabine hydrochloride	5,354,760	Mar 24, 2012
SEROQUEL	Astrazeneca	quetiapine fumarate	4,879,288*PED	Mar 26, 2012
SEROQUEL XR	Astrazeneca	quetiapine fumarate	4,879,288*PED	Mar 26, 2012
NUEDEXTA	Avanir Pharms	dextromethorphan hydrobromide; quinidine sulfate	5,206,248	Mar 27, 2012
FLOXIN OTIC	Daiichi	ofloxacin	5,401,741	Mar 27, 2012
AVALIDE	Sanofi Aventis	hydrochlorothiazide; irbesartan	5,270,317*PED	Mar 30, 2012
AVAPRO	Sanofi Aventis Us	irbesartan	5,270,317*PED	Mar 30, 2012